People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Luminary Therapeutics, Inc. | — | Biotechnology | Series A | $14.5M | $4.0M | 2022 |
Mark Chance at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Chance on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeff Ross | 1 | 4 |
| John Hurley | 1 | 3 |
| Jeff Liter | 1 | 3 |
| Branden Moriarity | 1 | 2 |
| David Largaespada | 1 | 2 |
| John Wells | 1 | 2 |
| Peter Kosa | 1 | 1 |
| George Cox | 1 | 1 |
| Tracey Lodie | 1 | 1 |
| Jim Haymaker | 1 | 1 |
| James Haymaker | 1 | 1 |
| Alexander Naydich | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.